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ABSTRACT
Whooping cough, which is caused by Bordetella pertussis and B. parapertussis, is a reemerging
disease. New protective antigens are needed to improve the efﬁcacy of current vaccines against
both species. Using proteomic tools, it was here found that B. parapertussis expresses a homolog
of AfuA, a previously reported new vaccine candidate against B. pertussis. It was found that this
homolog, named AfuABpp, is expressed during B. parapertussis infection, exposed on the surface
of the bacteria and recognized by speciﬁc antibodies induced by the recombinant AfuA cloned
from B. pertussis (rAfuA). Importantly, the presence of the O-antigen, a molecule that has been
found to shield surface antigens on B. parapertussis, showed no inﬂuence on antibody
recognition of AfuABpp on the bacterial surface. The present study further showed that
antibodies induced by immunization with the recombinant protein were able to opsonize B.
parapertussis and promote bacterial uptake by neutrophils. Finally, it was shown that this antigen
confers protection against B. parapertussis infection in a mouse model. Altogether, these results
indicate that AfuA is a good vaccine candidate for acellular vaccines protective against both
causative agents of whooping cough.
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Whooping cough, a vaccine-preventable disease, is
caused by B. pertussis and B. parapertussis. Introduction
of a wP vaccine, composed of heat-killed B. pertussis, has
signiﬁcantly decreased its incidence (1). In the 1990s,
concerns about the reactogenicity of wP vaccines led to
introduction of aP vaccines composed of puriﬁed B.
pertussis antigens. These acellular vaccines are currently
used for both primary vaccination of children and
booster immunization of adolescents and adults in an
attempt to control spread of these bacteria. Despite this
high worldwide vaccine coverage, in the last few decades
increased whooping cough outbreaks have been re-
ported in many countries (2–6). Replacement of the wP
vaccine by the safer but less effective aP vaccines is
thought to have contributed to reemergence of whoop-
ing cough. aP vaccines are not only less effective against
B. pertussis (1), but also do not induce protection against
B. parapertussis (7); thus, since their introduction, the
incidence of whooping cough caused by B. parapertussis
has increased, as shown by epidemiological studies (8, 9).
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This lack of cross protection is attributable both to
antigenic variability between these species (10, 11) and to
the presence on the surface of B. parapertussis of the O-
antigen, which interferes with the eventual opsonic
activity of aP vaccine-induced antibodies (7).
Antibody-mediated bacterial phagocytosis by PMNs
or macrophages has been found to be critical to inducing
bactericidal activity against B. parapertussis (12, 13) and
protection against infection (7). In the absence of
opsonic antibodies, bacterial uptake by these immune
cells is not only less efﬁcient but, more importantly, does
not result in killing of bacteria (12, 13). Thus, new
antigens capable of inducing opsonic activity against B.
parapertussis may signiﬁcantly improve the efﬁcacy of
whooping cough acellular vaccines.
Antigenic proteins that are expressed during infection
and exposed on the surface of B. parapertussis may
constitute good targets for opsonins. Using a proteomic
approach, we have previously detected antigenic pro-
teins exposed on the surface of B. pertussis under
conditions of iron limitation (14), an environmental
condition that human pathogens face during host
infection (15). Two of these proteins, AfuA (BP1605)
and IRP1-3 (BP1152), which are involved in vital iron
uptake systems (16, 17) and expressed in the infective
phenotype, proved to be good targets for opsonins and
highly protective against infection (18, 19). In the
present study, a homolog of AfuA was found to be
expressed in iron-starved B. parapertussis and its
potential as a protective antigen against B. parapertussis
infection was investigated.
MATERIALS AND METHODS
Bacterial strains and growth conditions
B. parapertussis strain CN2591 and its isogenic mutant
strain lacking the O-antigen (BppDwbm) (20, 21) were
used in this study. B. parapertussis strains were cultured
in SSmediumunder iron-sufﬁcient (SS) and iron-depleted
(SS-Fe) conditions, as previously described (14).
As previously described, Escherichia coli BL21-
CodonPlus (DE3)-RIL transformed with plasmid
pET28/His6-AfuA (19) was used in expression experi-
ments. rAfuA was obtained as described in (19) and
adsorbed with sepharose–polymyxin B (Sigma, St. Louis,
MO, USA) to eliminate LPS contamination.
Proteomic analysis
B. parapertussiswas grown in either SS or SS-Femedium.
Triplicate cultures were harvested and cell lysates
prepared and resolved using 2D gel electrophoresis, as
previously described (14) with minor modiﬁcations.
Brieﬂy, aliquots of cell extracts containing 0.2mg protein
were separated in the ﬁrst dimension by isoelectric
focusing in a Multiphor II Electrophoresis System (GE
Healthcare, Piscataway, NJ, USA) for a total of 5 kVh at
20°C using 7 cm linear immobilized pH gradients (pH
gradient of 3 to 10). The rehydration solution contained
7M urea, 2M thiourea, 33.4mM dithiothreitol, 1%
Triton X-100 and 2% Pharmalyte (broad range, pH 3 to
10). Proteins were separated in the second dimension by
using 10% SDS-PAGE and a Bio-Rad Mini-Protean
Tetra System (Bio-Rad, Hercules, CA, USA). Gels were
stained using colloidal Coomassie blue G250. Spot
detection, matching, abundance quantiﬁcation and
normalization were performed using the software Image
J. The protein pattern of each growth condition was
assessed on the basis of gels from three independent
cultures. The protein spots of interest were excised,
destained using ammonium bicarbonate in acetonitrile,
reduced with dithiothreitol for 30min, and then digested
with trypsin in ammonium bicarbonate overnight
(37°C). Peptides were extracted at 37°C using 1:2 (v/v)
5% formic acid/acetonitrile, and reconstituted in 0.1%
(v/v) triﬂuoracetic acid. The resulting digested mixture
was then analyzed by Autoﬂex (Bruker Daltonics,
Bremen, Germany) MALDI-TOF-MS. The sample:
matrix (a-cyano-4-hydroxycinnamic acid) (1:1) were
spotted onto a ground-steel sample target (Bruker
Daltonics) and the instrument calibrated using Peptide
Calibration Standard (Bruker Daltonics). All samples
were analyzed in positive reﬂector ionization mode
(Autoﬂex II; Bruker Daltonics) and the PMF generated.
Protein identiﬁcation was carried out using the Mascot
search engine (22) and Biotools software, version 3.1
(Bruker Daltonics). PMF lists were searched against the
NCBI database. The restricting taxonomy frame for the
search was set to “other proteobacterias” and the Mascot
score probability set for P< 0.05 and under the following
conditions: peptide mass tolerance, 10 ppm; variable
modiﬁcation, carbamidomethylation; and variable
modiﬁcation, oxidation.
Cells
Peripheral blood PMN were isolated from human
heparinized venous blood using Ficoll-Histopaque
(Sigma) gradient centrifugation, as previously de-
scribed (23). All procedures involving human samples
were in performed accordance with the ethical standards
of the 1964 Helsinki declaration and its later amend-
ments, and approved by the Institutional Review Board.
Peripheral blood was collected from healthy donors. All
individuals provided written informed consent for the
collection of samples and subsequent analysis.
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Animal experiments
Three to six week old female BALB/c mice were used in
animal experiments. The mice were obtained from and
bred in the speciﬁc pathogen-free breeding rooms of the
animal facility of the Faculty of Veterinary, University of
La Plata.
Mice were immunized as previously described (19).
Brieﬂy, groups of seven BALB/c mice were immunized
intraperitoneally with 10mg of rAfuA protein obtained
as previously described (19) and emulsiﬁed in complete
FA. Twenty one days after the ﬁrst immunization, a
booster dose with the same amount of recombinant
protein emulsiﬁed in incomplete FA was given. As
negative control, seven mice were immunized with an
equal amount of adjuvant alone. The mice were bled on
Days 0, 21 and 36. Serum was separated by centrifuga-
tion and stored at 20°C until analysis.
For challenge, ﬁfteen days after the last immunization,
groups of seven immunized mice were sedated and
challenged by pipetting 50mL of PBS containing
1.5 106 CFU of B. parapertussis grown in SS-Fe onto
the external nares, as previously described (24). Three
days after challenge, the mice were killed and their lungs
excised, homogenized in PBS, serial diluted, plated onto
BGA plates supplemented with 15% deﬁbrinated sheep
blood (Laboratorio Argentino, Caseros, Argentina) and
incubated at 37°C, after which CFU were counted.
Sera from convalescent mice were obtained as
previously described (25) with minor modiﬁcations.
Brieﬂy, groups of four mice were sedated and inoculated
by pipetting 50mL of PBS containing 1.5 106 CFU of B.
parapertussis onto the external nares and serum samples
collected on Day 28 post inoculation. Sera from mice
inoculated with PBS were used as controls.
Animal handling and all experimental procedures
were carried out in compliance with ARRIVE guidelines
and in accordance with the European Union Directive
for Animal Experiments 2010/63/EU. The animal
experiments described in this study were reviewed and
approved by the Institutional Animal Care and Use
Committee.
ELISA
Antibody titers were determined by ELISA, as previously
described (19) with minor modiﬁcations. Brieﬂy, twofold
diluted samples were assayed in 96-well polystyrene
microtiter plates that were coated with 10mg/mL of
recombinant protein in coating buffer (0.5M carbonate
buffer, pH 9.5), wild type B. parapertussis grown either in
SS or SS-Fe (OD:1) in PBS or BppDwbm grown in SS-Fe
(OD:1) in PBS. A HRP-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch,West Grove, PA) was used to
detect bound IgG. For measuring IgG isotypes, amounts
of bound antibody were determined using HRP-labeled
subclass-speciﬁc anti-mouse IgG1 or IgG2a (Santa Cruz
Biotechnology, SantaCruz,CA,USA).Titer, calculated by
an endpoint method (26), was deﬁned as the reciprocal of
the highest serum dilution that gave a reading above the
cutoff.
Phagocytosis assay
Phagocytosis of B. parapertussis was evaluated as
previously described (12) with minor modiﬁcations.
Brieﬂy, wild type B. parapertussis or BppDwbm grown in
SS-Fe were opsonized by 30min incubation at 37°C with
either rAfuA-induced or na€ıve mouse serum. Opsonized
bacteriawerewashed and further incubatedwithPMN for
10min at 37°C to allow interaction (MOI 50), extensively
washed at 4°C to remove non-attached bacteria and
further incubated for 40min at 37°C. Phagocytosis was
stopped by placing PMNon ice. Cells were ﬁxed using 4%
paraformaldehyde, washed once with PBS and incubated
for 10min at room temperature with PBS containing
50mM NH4Cl. PMN surface-bound bacteria were
detected by a two-step antibody dependent labeling
procedure as follows. PMN were incubated with
polyclonal rabbit anti-B. parapertussis antiserum
(30min at 4°C), followed by incubation with cyanine 3-
conjugated goat F(ab0)2 fragments of anti-rabbit immu-
noglobulin (Jackson ImmunoResearch) for another
30min at 4°C. To determine the number of intracellular
bacteria, cells were washed and permeabilized by
incubation with PBS containing 0.1% saponin (Sigma)
and 0.2% BSA for 30min, and further incubated for other
30min with rabbit anti-B. parapertussis antiserum in the
presence of 0.1% saponin and 0.2% BSA. After washing
three times, PMN were incubated for 30min with FITC-
conjugated F(ab0)2 fragments of anti-rabbit immuno-
globulin (Jackson ImmunoResearch). Bacterial phagocy-
tosis by PMN was evaluated by ﬂuorescence microscopy
using a confocal laser scanning microscope (Leica TCS
SP5; Leica, Heidelberg, Germany). The number of
extracellular (red and green ﬂuorescent) and intracellular
bacteria (green ﬂuorescent) per cell was determined by
microscopic examination of at least 10 randomly selected
ﬁelds with a minimum of ﬁve cells per ﬁeld. To avoid
eventual cytophilic binding of antibodies to FcgR, all
incubations were done in the presence of 25% heat-
inactivated human serum. All experiments were carried
out at least twice in triplicate.
Immunoblot analysis
Puriﬁed rAfuA, whole cell lysates or outer membrane
fractions from B. parapertussis obtained as previously
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described (14), were prepared with Laemmli sample
buffer and run on 10% SDS-PAGE. Proteins were
transferred to polyvinylidene ﬂuoride (Immobilon
PVDF Millipore) sheets and incubated with sera
from mice immunized with rAfuA. Immunochemical
detection was performed using alkaline phosphatase-
conjugated goat antimouse IgG (Jackson Immuno
Research).
Statistical analysis
Differences between the results of the experiments were
evaluated by mean of ANOVA or Student's t-test.
Signiﬁcance was accepted at P< 0.05. Results are shown
as means and SD.
RESULTS
B. parapertussis expresses AfuA
Two-dimensional gel electrophoresis was used to
investigate expression of AfuA in B. parapertussis by
analyzing whole cell lysates of the bacteria cultivated
under SS-Fe or SS conditions. Considering the isoelectric
points and molecular weights of the predicted AfuA (8.6
and 37.46 kDa, respectively), a number of proteins were
targeted for identiﬁcation in each gel. The spots were
submitted to tryptic digestion and MALDI-TOF-MS.
Two of them (shown in Fig. 1) were identiﬁed as AfuA
(BPP2980), hereafter called AfuABpp. As observed for
AfuA of B. pertussis, AfuABpp was more abundant in
iron-starved bacteria (spot value SS/SS-Fe: 0.310/3.118).
Antibodies induced by rAfuA recognize
AfuABpp
Western blot analysis of whole cell lysates and outer
membrane fractions of B. parapertussis cultivated under
SS or SS-Fe growth conditions showed that antibodies
raised against rAfuA recognized only one protein of the
molecular weight of AfuA in each sample (Fig. 2a),
indicating that antibodies raised againstB. pertussis
recombinant AfuA recognize the homolog in
B. parapertussis. As expected, they further show that
AfuABpp is present in the outer membrane fractions of
B. parapertussis.
Whole cell ELISA using live iron-starved or iron-
replete B. parapertussis as antigen was used to determine
AfuA antibody titers to evaluate whether AfuABpp is
exposed on the bacterial surface. Sera from mice
immunized with recombinant AfuA showed bacterial
recognition in both assays; however, titers were
signiﬁcantly higher in the ELISA in which iron-starved
bacteria were used as coating antigen (Fig. 2b). These
results not only conﬁrm that AfuABpp is iron-regulated,
but also indicate that AfuABpp is exposed on the surface
of the bacteria. Next, whether the O-antigen interferes
with antibody recognition of AfuABpp was evaluated. To
this end, whole-cell ELISA using an O-antigen-deﬁcient
mutant strain of B. parapertussis cultivated under iron
starvation as coating antigen was performed in parallel.
No signiﬁcant differences were observed between
AfuABpp recognition of the wild type and O-antigen
mutant strain of B. parapertussis (Fig. 2b), indicating that
the O-antigen has little or no effect on antibody
recognition of AfuABpp on the bacterial surface.
Anti-rAfuA antibodies promote PMN
phagocytosis of B. parapertussis
Antibody recognition as determined by ELISA does not
necessarily indicate biological activity. Therefore,
whether the antibodies induced by the recombinant
protein were able to induce opsonophagocytosis of B.
parapertussis by human PMN was then examined.
Figure 3 shows that anti-rAfuA antibodies signiﬁcantly
increased PMN phagocytosis of iron-starved
B. parapertussis as compared with na€ıve serum. Again,
the presence of the O-antigen did not interfere with the
biological activity of rAfuA-induced antibodies, as
indicated by the lack of signiﬁcant difference between
opsonophagocytosis of the O-antigen deﬁcient mutant
and the wild type strain of B. parapertussis (Fig. 3).
Fig. 1. 2D gel image showing AfuABpp
protein spots. Image J software was used for
protein spot detection, matching and
quantiﬁcation in 2D gels of B. parapertussis
growth in (a) SS and (b) SS-Fe. The protein spots
indicated with arrows were in-gel digested and
analyzed by MALDI-TOF-MS to create PMFs and
the PMFs identiﬁed by using MASCOT and
Biotools software (MS/MASCOT score, 212;
coverage, 26%).
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AfuABpp is expressed during infection
To investigate whether AfuABpp is expressed during
infection, the presence of antibodies against AfuA was
evaluated in sera from mice convalescing from B.
parapertussis infection. To that end, sera from na€ıve and
convalescent mice were analyzed by ELISA using
puriﬁed rAfuA as coating antigen. Only sera from
infected animals showed signiﬁcant amounts of anti-
AfuA antibodies (Fig. 4) suggesting that AfuABpp is
expressed during infection.
rAfuA protects mice against B.
parapertussis infection
Antibody responses induced in mice immunized twice
with rAfuA were investigated. Mice injected with the
adjuvant alone served as control. Immunization with
rAfuA induced an IgG speciﬁc response that was
already detectable 21 days after the ﬁrst immunization.
As previously found (19), repeated immunization led
to a booster response of speciﬁc IgG anti-rAfuA (log
titer: 6.7 0.25) with a balanced IgG1/IgG2a response
(Fig. 5).
To investigate whether rAfuA can protect against B.
parapertussis infection, mice immunized with rAfuA
were challenged intranasally with iron-starved B.
parapertussis. Mice immunized with FA alone were
used as negative controls. Protective activity was
evaluated by determining bacterial clearance in the
lungs. Control mice vaccinated with adjuvant alone
had mean loads around 107 CFU in the lungs 3 days
post challenge. Mice given rAfuA plus adjuvant
exhibited signiﬁcant protection (P< 0.05) against B.
parapertussis as compared with mice immunized with
adjuvant alone (Table 1).
DISCUSSION
Despite widespread vaccination programs focused on
whooping cough control, a resurgence of the disease has
been reported in the last few decades (2–6). Although
both B. pertussis and B. parapertussis can cause this
disease, efforts to improve preventive strategies have
been mainly focused on controlling circulation of B.
pertussis. However, several studies have suggested an
increasing incidence of B. parapertussis worldwide (8, 9,
27). This increase has been mainly attributed to the
introduction of aP vaccines that confers no protection
against this species (4, 7, 8). It has been shown by
individual evaluation in a mouse model that, except for
ﬁmbriae (28), none of the aP vaccine components confer
protection against B. parapertussis (10). Even in the case
of ﬁmbriae, the level of protection against B. para-
pertussis infection is reportedly lower than against B.
pertussis infection (28). Two possible causes for this lack
of cross protection have been identiﬁed. One of them is
the immunogenic variability of aP components between
the Bordetella species (10, 11, 28). The other is the
presence of the O-antigen on B. parapertussis surface.
Fig. 2. Antibodies induced by rAfuA recognize AfuABpp. (a)
Whole cell lysates (Lanes 1 and 2) and outer membrane proteins
(Lanes 3 and 4) from B. parapertussis grown either under iron
starvation (Lanes 1 and 3) or iron excess (Lanes 2 and 4) cultural
conditions were subjected to SDS-PAGE (10%) and immunoblot
analysis using anti-rAfuA antibodies. rAfuA was run as positive
control (Lane 5). The gel was loaded with equivalent ODs in Lanes 1
and 2, and the same amount of protein in Lanes 3 and 4. (b)
Antibody titers induced in mice by immunization with rAfuA were
determined by whole cell ELISA. Plates were coated with either iron-
starved BppDwbm or Bppwt grown under iron-replete or iron-
depleted conditions. Sera from mice immunized with rAfuA showed
signiﬁcantly stronger reactions with iron-starved Bppwt than with
Bppwt grown under iron-replete conditions (P < 0.05). Antibody
titers are expressed as the mean of the log of the end point titer of
each serum SD.
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Zhang et al.have shown that theO-antigen interfereswith
bacterial recognition by aP induced antibodies (7).
However, immunization of mice with aP vaccine does
not protect them against infection with an O-antigen
deﬁcient B. parapertussis mutant strain (7), indicating
that other factors, such as antigenic variability, are
involved in failure of aP vaccines against B. parapertussis.
Clinical and epidemiological data show the need for
better preventive strategies against whooping cough,
including vaccines that perform better against both B.
pertussis and B. parapertussis. To our knowledge, only a
few antigens have been proposed as potential acellular
vaccine candidates against B. parapertussis. Komatsu
et al. showed that immunization with B. parapertussis
ﬁlamentous hemagglutinin protects against infection
and proposed development of acellular vaccines against
B. parapertussis composed of ﬁlamentous hemagglutinin
and other antigens puriﬁed from this pathogen (29).
Other studies have suggested O-antigen as a candidate to
be included in current pertussis vaccines (25). However,
to our knowledge, this antigen has not yet been
evaluated.
We previously used a comparative proteomic analysis
to search for new vaccine components able to improve
immunity against B. pertussis (14) and identiﬁed an iron-
repressed protein, named AfuA (BP1605), expressed
during infection that proved to be protective against this
pathogen (19). In the present study, we analyzed B.
parapertussis response to iron starvation and observed
that expression of BPP2980, the homolog of B. pertussis
AfuA, is also induced under this environmental
condition. This protein, named AfuABpp, has consider-
able sequence similarity (99.4% of identity) with AfuA of
Fig. 3. B. parapertussis opsonophagocytosis induced by anti-rAfuA antibodies. (a) Bppwt or BppDwbm grown under iron-depleted
conditions were incubated with anti-rAfuA or na€ıve serum for 30min at 37°C, washed, and further incubated with PMN (MOI 50) for 10min at
37°C. After attachment, PMN were washed and further incubated for 40min at 37°C to allow internalization. Cells were ﬁxed and intracellular
bacteria labelled with green and extracellular bacteria with both green and red ﬂuorescent dyes. Bacterial phagocytosis was assessed by confocal
laser scan ﬂuorescence microscopy. At least 50 cells per slide were counted. PMN phagocytosis of anti-rAfuA opsonized Bppwt and anti-rAfuA
opsonized BppDwbm differed signiﬁcantly from PMN phagocytosis of na€ıve serum opsonized Bppwt and BppDwbm, respectively (P< 0.05).
Data represent the mean SD of two independent experiments with PMN from different donors. (b) Confocal ﬂuorescence microscopy of PMN
incubated 40min at 37 °C with (b1, b2) Bppwt or (b3, b4) BppDwbm opsonized with (b1, b3) anti-rAfuA or (b2, b4) na€ıve serum. Representative
panels of one of two independent experiments are shown.
Fig. 4. AfuA is expressed during B. parapertussis infection. Anti-
AfuA antibody titers induced in mice infected with B. parapertussis
were determined by ELISA. Plates were coated with rAfuA as antigen.
Sera of infected mice had signiﬁcantly higher anti-AfuA antibody
titers than sera of na€ıve mice (P< 0.05). Antibody titers are
expressed as the end point titer of each serum. The respective mean
titer of each group is shown.
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B. pertussis. The differences between the species are in
residues 31 and 149. According to bioinformatics
analysis, only residue 31 may be part of an epitope. In
particular, it may be part of one of the 18 linear B-cell
predicted epitopes (30). The reported crystal structure of
BP1605 (Protein Data Bank code 1Y9U) includes only
the residue 149 and shows that this residue is neither
surface-exposed nor part of any structure-based epitope,
as predicted with discotope (31). Altogether, these
results suggest that there is low antigenic variability
between B. pertussis and B. parapertussis AfuA. In
agreement with these ﬁndings, we observed that anti-
bodies induced by recombinant AfuA cloned from B.
pertussis not only recognized AfuABpp in western blot
analysis of both whole cell lysates and outer membrane
fractions of B. parapertussis, but also recognized the
protein on bacterial surfaces, as determined by whole cell
ELISA. We conﬁrmed the biological activity of rAfuA-
induced antibodies in opsonophagocytosis studies using
freshly isolated human neutrophils. Our results indicate
that antibodies raised against rAfuA are able to opsonize
B. parapertussis and promote bacterial phagocytosis by
neutrophils, conﬁrming not only surface exposure of the
AfuABpp, but also recognition of the native protein by
rAfuA-induced antibodies. Importantly, we observed
that the O-antigen does not hamper antibody recogni-
tion of AfuABpp. The presence of the O-antigen did not
interfere with antibody detection of AfuABpp in either
ELISA or in functional studies.
Both neutrophils and opsonic antibodies are reportedly
crucial to controlling B. parapertussis infection (32).
According to previous studies, this pathogen is able to
survive innate interactions with neutrophils (12, 33) and
macrophages (13). In the absence of opsonins, phagocy-
tosed B. parapertussis remains viable inside both types of
immune cells and eventually replicates inside macro-
phages, which may constitute an intracellular niche of
persistence (12, 13). Currently available acellular vaccines
do not induce opsonic antibodies against B. parapertus-
sis (7). Of the antigens present in aP vaccines, pertactin is
theonly one able to induceopsonins (34). In addition to the
O-antigen effect on antibody recognition (7) and the
reported antigenic variability between B. pertussis and B.
parapertussis pertactin (10), in the last few years B.
parapertussis circulating strains that do not express this
antigen have emerged (35, 36). We have previously found
that antibodies raised against rAfuA are able to opsonizeB.
pertussis and promote efﬁcient bacterial phagocytosis by
human neutrophils (19). In the present study, we showed
that anti-rAfuA antibodies induced by recombinant AfuA
cloned from B. pertussis are also able to opsonize B.
parapertussis and promote bacterial uptake by neutrophils,
which adds value to AfuA as a potential candidate for
whooping cough control. Conﬁrming the relevance of
AfuA as a promising new protective immunogen,
immunization of mice with rAfuA induced signiﬁcant
protection against B. parapertussis proliferation in the
lungs as compared with control mice.
In summary, better preventive approaches against
whooping cough should include new vaccines protective
against B. parapertussis. Previous studies have pointed
out AfuA as a potential candidate for improving vaccines
against B. pertussis. The data presented in this study
indicate that this protein also confers protection against
B. parapertussis, shedding new light on the potential of
this antigen as a promising candidate for improving
vaccines against whooping cough.
Fig. 5. Anti-rAfuA antibody isotype proﬁle. Anti-rAfuA IgG1 and
IgG2a antibody titers were determined by ELISA 15 days after booster
immunization with rAfuA (Day 36). Antibody titers are expressed as
the mean of the log of the end point titer of each serum SD.
Table 1. Protection against B. parapertussis infection induced by
rAfuA immunization
Vaccine Log CFU in lungs† Units of protection‡
rAfuA/FA 5.96 0.24§ 0.97
PBS/FA 6.93 0.06 —
†Content of bacteria in lungs is presented as the mean log CFU SD per
group; ‡units of protection were obtained by subtracting the mean log
CFU of the vaccinated group from the mean log CFU of the control
group; §signiﬁcantly different from FA-immunized mice (P< 0.05).
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